Patients with bipolar II disorder benefit from single dose of psilocybin
The Brown University Psychopharmacology Update March 4, 2024 DOI: 10.1002/pu.31143 via OpenAlex
Summary
AI-generated from the abstractA single 25 mg dose of psilocybin led to improvement in depressive symptoms in all 15 adults with bipolar II disorder in an open-label nonrandomized trial. Twelve of the 15 participants met response and remission criteria at the 12-week endpoint.
Study at a glance
| Characteristics | Open-label nonrandomized trial Peer reviewed |
|---|---|
| Sample size | 15 |
| Population | Adults with bipolar II disorder |
| Intervention | Psilocybin |
| Dose | 25 mg |
| Duration | 12-week endpoint |
| Topics | Psilocybin |
| Keywords | Bipolar disorder Medicine Pharmacology Neuroscience |
| Key finding | A single 25 mg dose of psilocybin improved depressive symptoms in all 15 participants, with 12 meeting response and remission criteria at 12 weeks. |
Abstract
A single 25‐mg dose of psilocybin resulted in improvement in depressive symptoms in all 15 participants in an open‐label nonrandomized trial enrolling adults with bipolar II disorder. Twelve of the 15 participants met response and remission criteria at the study's 12‐week endpoint.